H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33

Aktis Oncology, Inc. (NASDAQ:AKTS) is one of the 8 Healthcare Stocks Insiders Are Buying. On March 31, 2026, H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology, Inc. (NASDAQ:AKTS) to $33 from $30 previously and maintained a Buy rating on the shares. Robert Burns has said that the company’s pipeline is expected to advance and expand over the next twelve months.

On March 30, 2026, Aktis Oncology, Inc. (NASDAQ:AKTS) announced the FDA clearance of investigational new drug applications to begin a Phase 1b trial for AKY-25191, a miniprotein radioconjugate targeting B7-H3 across multiple solid tumors, including prostate and lung cancers.

Aktis Oncology, Inc. (NASDAQ:AKTS) said that AKY-2519 is its second clinical-stage miniprotein radioconjugate, while its lead program, AKY-1189, targeting Nectin-4, is already enrolling in a Phase 1b study, with both designed to deliver actinium-225 to tumor sites.

Aktis Oncology, Inc. (NASDAQ:AKTS) develops radiopharmaceutical therapies for solid tumors.

While we acknowledge the risk and potential of AKTS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AKTS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.